Popular Trials
Tyrosine Kinase Inhibitor
Nilotinib + Radiation for Chordoma
This trial is testing a drug, nilotinib, to see if it can help shrink tumors when used with radiation therapy. Researchers want to see if it is safe and what the highest dose is that can be given without causing severe side effects.
Proton Beam Therapy
Intensity Modulated Proton Radiation for Brain & Spine Cancer
This trial is testing a new way to give proton radiation therapy for tumors in the brain and spine. The new way, called intensity modulated proton radiation therapy (IMPT), may be more accurate and have fewer side effects than the standard proton radiation therapy.
Popular Filters
Trials With No Placebo
Histone Methyltransferase Inhibitor
Tazemetostat + Immunotherapy for Cancer
This trial tests a combination of three drugs to treat children with specific hard-to-treat cancers. The drugs work by blocking cancer growth and boosting the immune system. The study aims to find the safest dose and see if the combination is effective.
Monoclonal Antibodies
Cetuximab for Chordoma
This trial is testing cetuximab, a medication that blocks a protein on cancer cells, in adults with advanced or metastatic chordoma. These patients have cancers that cannot be surgically removed or have spread to other parts of the body. The goal is to see if cetuximab can help stop the cancer from growing and spreading. Cetuximab is approved for various cancers including colorectal and head and neck cancers.
Monoclonal Antibodies
BCA101 + Pembrolizumab for Cancer
This trial is testing BCA101, a new drug that targets specific cancer growth proteins, in patients with advanced cancers that haven't responded to other treatments. The drug works by blocking proteins that help the cancer grow and spread.
Checkpoint Inhibitor
Nivolumab +/− Stereotactic Radiosurgery for Chordoma
This trial is studying nivolumab with or without SRS to treat patients with chordoma. Nivolumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. SRS is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor.
View More Related Trials
Frequently Asked Questions
Introduction to chordoma
What are the top hospitals conducting chordoma research?
When it comes to pioneering clinical trials in the realm of chordoma research, several prominent hospitals are leading the charge. In Boston's medical landscape, Massachusetts General Hospital stands out with five ongoing chordoma trials, contributing to a total of nine conducted studies since their first trial was recorded in 1999. The Dana-Farber Cancer Institute, another renowned facility in the city, is currently conducting three active chordoma trials while having completed four previous investigations since their inaugural trial in 1999 as well. Not to be overlooked is New york City's Memorial Sloan Kettering Cancer Center, where researchers are actively exploring this rare bone cancer through three ongoing clinical trials and have previously carried out four additional studies following their initial involvement with chordoma research also back in 1999.
Boston Children's Hospital plays an important role too by delving into two current chordoma trials while holding a record for two prior investigations; they commenced their journey towards understanding this condition only last year in 2020. Meanwhile, Mayo Clinic - Jacksonville contributes significantly from Florida with its two active chordoma trials and two historically held investigations; theirs can be traced back six years ago when they initiated their first trial specifically targeting this disease.
These esteemed hospitals demonstrate not only dedication but also remarkable progress toward unraveling the complexities of chordoma—providing hope for those affected by this rare form of bone cancer. Together, these institutions offer a beacon of optimism that every step forward brings us closer to improved treatments and ultimately finding a cure for patients battling this challenging condition across the nation
Which are the best cities for chordoma clinical trials?
Boston, Massachusetts; Los Angeles, California; and Anchorage, Alaska are recognized as leading cities for chordoma clinical trials. Boston takes the lead with 12 active studies focused on investigating treatments like Tazemetostat, Nivolumab, and TAEK-VAC-HerBy. Los Angeles follows closely behind with 9 ongoing trials studying options such as Nivolumab, BCA101, and Arm B (atezolizumab, tiragolumab). Anchorage also demonstrates promising research efforts with 8 active trials primarily exploring the use of Nivolumab in treatment approaches. These cities offer individuals diagnosed with chordoma invaluable access to cutting-edge clinical trials that drive advancements in care and provide hope for improved outcomes.
Which are the top treatments for chordoma being explored in clinical trials?
Exciting advancements are taking place in clinical trials for chordoma, with several promising treatments at the forefront. Nivolumab leads the pack with three ongoing trials and a total of six all-time chordoma trials since its debut in 2017. Tazemetostat follows closely behind, showing potential in two active and two all-time chordoma studies since 2015. Cetuximab, TAEK-VAC-HerBy, and FAZ053 also show promise, each being explored in one active trial along with their respective all-time chordoma trial records. As researchers delve deeper into these innovative treatments, hope grows brighter for patients battling this rare cancerous tumor originating from bone or soft tissue.
What are the most recent clinical trials for chordoma?
Recent clinical trials offer hope for patients with chordoma, a rare type of cancer that develops in the bones of the skull and spine. One promising study is investigating the effectiveness of tazemetostat, which has shown potential in both Phase 1 and Phase 2 trials. Another trial focuses on Arm B, combining atezolizumab and tiragolumab to explore their impact on chordoma treatment. Additionally, cetuximab and nivolumab have demonstrated encouraging results in separate Phase 2 studies. These advancements provide new possibilities for improving outcomes and quality of life for individuals affected by this challenging disease.
What chordoma clinical trials were recently completed?
Recently completed clinical trials for chordoma have made significant strides in advancing treatment options for this challenging condition. In September 2019, the John Wayne Cancer Institute concluded a trial investigating the efficacy of Pemetrexed. Additionally, in October 2018, Bavarian Nordic completed a trial evaluating BN-Brachyury in combination with radiation therapy. Another noteworthy study was conducted by Intensity Therapeutics, Inc., who wrapped up their investigation into INT230-6 in February 2017. These recent advancements offer hope and highlight the dedication of researchers to find innovative solutions for patients with chordoma.